NICE Recommends Pfizer’s Bosulif Following Cancer Fund Reform

The UK’s price watchdog is backing coverage for Pfizer’s Bosulif at a new discounted price, broadening access to the drug that was previously only available through the now-revamped Cancer Drugs Fund.

Bosulif is the first cancer fund drug to secure NICE approval under a reappraisal process which began earlier this month to address overspending concerns.

The once-distinct cancer fund was restructured and brought under NICE’s purview as a managed access fund following years of uncontrolled spending. As part of the process, NICE is reviewing all of the drugs cleared by the fund.